Skip to main content
Dr. Lal Pathlabs Limited logo

Dr. Lal Pathlabs Limited — Investor Relations & Filings

Ticker · LALPATHLAB ISIN · INE600L01024 LEI · 984500E8E9CY102B9718 BSE.NS Human health and social work activities
Open in API
Filings indexed 1,098 across all filing types
Latest filing 2021-05-21 Earnings Release
Country IN India
Listing BSE.NS LALPATHLAB

About Dr. Lal Pathlabs Limited

https://www.lalpathlabs.com/

Dr. Lal Pathlabs Limited is a provider of diagnostic and related healthcare tests and services. The company offers a comprehensive range of clinical laboratory tests and profiles used for prediction, early detection, diagnostic screening, confirmation, and monitoring of diseases. Its service portfolio encompasses pathology, including biochemistry, hematology, clinical pathology, histopathology, and molecular diagnostics, as well as radiology services such as X-ray, ultrasound, and CT scans. The organization operates an extensive network of laboratories, patient service centers, and pick-up points, utilizing advanced automated systems and standardized processes. Key offerings include specialized wellness packages and home sample collection. The company maintains high quality standards through international and national accreditations, serving a diverse patient base and healthcare providers with a focus on accuracy and timely reporting.

Recent filings

Filing Released Lang Actions
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated May 21, 2021, announcing the audited financial results (standalone and consolidated) for the quarter and financial year ended March 31, 2021. It includes detailed financial highlights such as revenue, EBITDA, PBT, PAT, and EPS for Q4 FY 2020-21 and FY 2020-21, along with comparative figures from the previous year. The document also mentions a final dividend approved by the board. The content is typical of an Earnings Release (ER) as it provides key financial results and highlights for a specific quarter and fiscal year, rather than a full annual report or detailed management discussion. The length is just over 5,000 characters, and the document is a direct announcement of financial results, not merely a notification of a report publication. Therefore, the most appropriate classification is Earnings Release (ER). FY 2021
2021-05-21 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is titled as an "Earnings Presentation on Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial Year ended March 31, 2021." It contains detailed financial data including revenues, EBITDA, PAT, EPS, and segment performance for Q4 FY21 and FY21. The document is a presentation intended for analysts and investors, as indicated by the subject and disclaimers. It includes financial highlights, performance snapshots, and management commentary. The length is about 15,000 characters, indicating a full presentation rather than a brief announcement. This matches the definition of an Investor Presentation (IP), which is a detailed presentation focusing on financials, strategy, and market position. It is not a simple earnings release (ER) because it contains detailed financial data and analysis, nor is it an Annual Report (10-K) or Interim Report (IR) as it is specifically a presentation document. Therefore, the correct classification is Investor Presentation (IP).
2021-05-21 English
Record Date
Annual Report Classification · 95% confidence The document is a detailed announcement from the Board of Directors regarding the approval of audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2021. It includes the auditor's report with an unmodified opinion, detailed audit procedures, and responsibilities. The document references Regulation 33 of SEBI Listing Regulations, which pertains to financial results disclosures. The content includes comprehensive audit opinions, financial results, and management responsibilities, indicating it is the actual audited financial report rather than a brief announcement or certification. The length (15,000 characters) and detailed financial and audit information confirm it is a full Annual Report type document. Therefore, the filing type is Annual Report (10-K). FY 2021
2021-05-21 English
Dividend
Annual Report Classification · 95% confidence The document is a detailed announcement from the Board of Directors regarding the approval of audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2021. It includes the auditor's report with an unmodified opinion, detailed audit responsibilities, and management's responsibilities. The document references Regulation 33 of SEBI Listing Regulations, which pertains to financial results disclosures. The content includes comprehensive financial data, audit opinions, and management commentary, indicating it is the actual audited financial report rather than a mere announcement or certification. The length (15,000 characters) and detailed financial and audit information confirm it is a full Annual Report or equivalent. Therefore, the document fits the definition of an Annual Report (10-K) filing type. FY 2021
2021-05-21 English
Financial Result Updates
Audit Report / Information Classification · 95% confidence The document is a detailed communication from the Board of Directors of Dr. Lal PathLabs Limited dated May 21, 2021, addressed to stock exchanges, reporting the approval of audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2021. It includes the auditor's report with an unmodified opinion from Deloitte Haskins & Sells LLP, which is a statutory audit firm. The document contains extensive audit opinion text, management responsibilities, and auditor responsibilities, indicating it is the actual audit report on the annual consolidated financial results, not just an announcement or summary. The presence of detailed audit procedures and conclusions confirms this is a standalone Audit Report / Information filing rather than the full Annual Report or a simple earnings release. Therefore, the appropriate classification is Audit Report / Information (AR). FY 2021
2021-05-21 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is an invitation and intimation of a conference call scheduled for May 21, 2021, to discuss the Q4 and full fiscal year 2021 financial and operating performance of Dr. Lal PathLabs Ltd. It includes details about the call, participants, dial-in numbers, and registration instructions. There is no actual financial data or detailed transcript of the call included. The document is essentially an announcement of the upcoming earnings conference call, not the earnings release itself or the transcript. Therefore, it fits the category of a Call Transcript (CT) only if it contained the transcript, but since it is only an invitation, it is best classified as a Regulatory Filing (RNS) as a general regulatory announcement about the conference call. However, given the options, the closest specific category is Call Transcript (CT) because it is about the earnings call, but since it is only an invitation and not a transcript, the correct classification is Regulatory Filings (RNS). Confidence is high because the document clearly states it is an invitation and not the transcript or earnings release.
2021-05-18 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.